Allogene Therapeutics, Inc. Depreciation
Allogene Therapeutics, Inc. (ALLO) reported Depreciation of $3.56 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2024-05-13
- Allogene Therapeutics, Inc. depreciation for the quarter ending 2024-03-31 was $3.56M, a 1.37% increase year-over-year.
- Allogene Therapeutics, Inc. depreciation for the quarter ending 2023-12-31 was $3.48M, a 13.33% increase year-over-year.
- Allogene Therapeutics, Inc. depreciation for the quarter ending 2023-09-30 was $3.57M, a 7.46% decline year-over-year.
- Allogene Therapeutics, Inc. depreciation for the quarter ending 2023-06-30 was $3.64M, a 0.87% decline year-over-year.
- Allogene Therapeutics, Inc. depreciation for fiscal 2023 was $14.20M, a 0.67% decline from fiscal 2022.
- Allogene Therapeutics, Inc. depreciation for fiscal 2022 was $14.29M, a 36.74% increase from fiscal 2021.
- Allogene Therapeutics, Inc. depreciation for fiscal 2021 was $10.45M, a 40.61% increase from fiscal 2020.
- Allogene Therapeutics, Inc. depreciation for fiscal 2020 was $7.43M, a 68.06% increase from fiscal 2019.
| Period end | Depreciation 1 month | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|---|
| 2024-03-31 | $3.56M 10-Q · filed 2024-05-13 | $7.03M derived: sum of 2 quarters · filed 2024-05-13 | $10.60M derived: sum of 3 quarters · filed 2024-05-13 | $14.25M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2023-12-31 | $3.48M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $7.05M derived: sum of 2 quarters · filed 2024-03-14 | $10.69M derived: sum of 3 quarters · filed 2024-03-14 | $14.20M 10-K · filed 2024-03-14 | |
| 2023-09-30 | $3.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $7.21M derived: sum of 2 quarters · filed 2023-11-02 | $10.72M 10-Q · filed 2023-11-02 | $13.79M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2023-06-30 | $3.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $7.15M 10-Q · filed 2023-08-02 | $10.22M derived: sum of 3 quarters · filed 2024-05-13 | $14.08M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2023-03-31 | $3.51M 10-Q · filed 2024-05-13 | $6.58M derived: sum of 2 quarters · filed 2024-05-13 | $10.44M derived: sum of 3 quarters · filed 2024-05-13 | $14.11M derived: sum of 4 quarters · filed 2024-05-13 | |
| 2022-12-31 | $3.07M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $6.93M derived: sum of 2 quarters · filed 2024-03-14 | $10.60M derived: sum of 3 quarters · filed 2024-03-14 | $14.29M 10-K/A · filed 2024-03-14 | |
| 2022-09-30 | $3.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $7.54M derived: sum of 2 quarters · filed 2023-11-02 | $11.23M 10-Q · filed 2023-11-02 | $15.47M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-06-30 | $3.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $7.37M 10-Q · filed 2023-08-02 | $11.61M derived: sum of 3 quarters · filed 2024-03-14 | $13.94M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2022-03-31 | $3.69M 10-Q · filed 2023-05-03 | $7.93M derived: sum of 2 quarters · filed 2024-03-14 | $10.26M derived: sum of 3 quarters · filed 2024-03-14 | $12.23M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-12-31 | $4.24M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $6.57M derived: sum of 2 quarters · filed 2024-03-14 | $8.54M derived: sum of 3 quarters · filed 2024-03-14 | $10.45M 10-K/A · filed 2024-03-14 | |
| 2021-09-30 | $2.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $4.29M derived: sum of 2 quarters · filed 2022-11-02 | $6.21M 10-Q · filed 2022-11-02 | $8.06M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-06-30 | $1.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $3.88M 10-Q · filed 2022-08-09 | $5.73M derived: sum of 3 quarters · filed 2024-03-14 | $7.54M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2021-03-31 | $1.92M 10-Q · filed 2022-05-04 | $3.76M derived: sum of 2 quarters · filed 2024-03-14 | $5.57M derived: sum of 3 quarters · filed 2024-03-14 | $7.46M derived: sum of 4 quarters · filed 2024-03-14 | |
| 2020-12-31 | $1.84M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $3.65M derived: sum of 2 quarters · filed 2024-03-14 | $5.54M derived: sum of 3 quarters · filed 2024-03-14 | $7.43M 10-K/A · filed 2024-03-14 | |
| 2020-09-30 | $1.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $3.70M derived: sum of 2 quarters · filed 2021-11-04 | $5.59M 10-Q · filed 2021-11-04 | $7.29M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-06-30 | $1.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $3.78M 10-Q · filed 2021-08-04 | $5.49M derived: sum of 3 quarters · filed 2022-02-23 | $6.66M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2020-03-31 | $1.89M 10-Q · filed 2021-05-05 | $3.60M derived: sum of 2 quarters · filed 2022-02-23 | $4.77M derived: sum of 3 quarters · filed 2022-02-23 | $5.77M derived: sum of 4 quarters · filed 2022-02-23 | |
| 2019-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $2.88M derived: sum of 2 quarters · filed 2022-02-23 | $3.88M derived: sum of 3 quarters · filed 2022-02-23 | $4.42M 10-K · filed 2022-02-23 | |
| 2019-09-30 | $1.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $2.18M derived: sum of 2 quarters · filed 2020-11-04 | $2.72M 10-Q · filed 2020-11-04 | ||
| 2019-06-30 | $999.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $1.54M 10-Q · filed 2020-08-05 | |||
| 2019-03-31 | $544.00K 10-Q · filed 2020-05-06 | ||||
| 2018-12-31 | $1.05M 10-K · filed 2021-02-25 | ||||
| 2017-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |